Solagran is a biotechnology company with a portfolio of higly effective, low side effect, natural pharmaceuticals that it obtains from gree tree foliage. Its patented technology enables the extraction of the live elements of trees in a way that both preserves and amplifies their biological activity. 
Solagran Limited (ASX: SLA) - Research Report on Solagran - Mr Denis Kilroy, Executive Director; Solagran Limited (ASX: SLA) present the following audio webcast regarding "Research Report on Solagran". You may also download this audio webcast to your computer or portable audio player.
Solagran Limited (ASX: SLA) - EGM Presentation - Mr Denis Kilroy, Executive Director and Mr Peter Stedwell, Executive Director; Solagran Limited (ASX: SLA) present the following audio webcast regarding "EGM Presentation". You may also download this audio webcast to your computer or portable audio player.
Shareholders of Melbourne-based Biotech Solagran (ASX: SLA) have approved a new investor-friendly approach to executive pay. The plan requires that the most senior Solagran executives put almost all of their income at risk on the basis of the amount of shareholder wealth created under their stewardship. Shareholders voted overwhelmingly to support the introduction of the plan at an EGM held yesterday.
Melbourne Biotech Solagran Limited (ASX: SLA) today announced that the Director of the Pasteur Institute in St Petersburg, Professor Anatoly Zhebrun DSc, has accepted the Board's invitation to visit Australia to discuss recently completed trials in relation to the use of Bioeffective(R) A in the prevention and treatment of Helicobacter Pylori infection.
Melbourne based Biotech Solagran Limited (ASX: SLA) today announced that arrangements were being put in place in St Petersburg to supply patients outside Russia with its liver disease drug Ropren, consistent with international regulatory guidelines.
Solagran Limited (ASX: SLA) - Pharmaceutical Registration of Bioeffective R and Ropren - Mr Denis Kilroy, Executive Director; Solagran Limited (ASX: SLA) present the following audio webcast regarding "Pharmaceutical Registration of Bioeffective R and Ropren". You may also download this audio webcast to your computer or portable audio player.
The Directors of Solagran Limited (ASX: SLA) are pleased to announce that the Company has received formal documentation from the Russian Ministry of Heath advising that pharmaceutical registration of both the substance Bioeffective® R and the medicine Ropren has been finalised.
The Directors of Solagran are pleased to announce a number of important decisions taken in relation to upgrading the company's Bioeffective(r) R manufacturing capacity.
The Directors of Solagran Limited (ASX: SLA) are pleased to release the attached letter which has been received from the organising committee of the Gastro-2007 Conference in St Petersburg.
Solagran Limited [B@8d9915; Boardroomradio is pleased to announce that Solagran Limited (ASX: SLA) has published an audio file.
